- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02323893
Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans
May 14, 2018 updated by: CellSight Technologies, Inc.
Study of the Kinetics, Dosimetry and Safety of [18F]F-AraG, a Positron Emission Tomography Tracer for Imaging the Activation of the Immune System in Healthy Humans
The goal of this study is to visualize biodistribution of a PET tracer called [18F]F-AraG through time in healthy human volunteers.
Study Overview
Detailed Description
A positron emission tomography (PET) imaging tracer will be intravenously injected into healthy human volunteers who provide informed consent.
Following injection of this tracer each volunteer will have four whole-body PET scans inside a PET scanner to obtain images of tracer biodistribution at four different time points.
This will allow studying the kinetics of the tracer as well analysis of tracer dosimetry.
Safety of the tracer will also be analyzed in each volunteer.
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Francisco, California, United States, 94107
- UCSF Imaging Center at China Basin
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy human subjects without history of chronic disease or at present an acute disease will be included.
- Ability to abide by the study conditions is also a requirement for inclusion.
Exclusion Criteria:
- Individuals under the age of 18 years and pregnant women will be excluded from the [18F]F-AraG imaging studies.
- Women who are breast-feeding will be excluded from the study.
- Individuals unable to provide informed consent will be excluded.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 18F-FAraG
A single dose intravenous injection of 18F-FAraG followed by PET scanning.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visualize biodistribution of the PET tracer [18F]F-AraG
Time Frame: 1 day
|
Whole-body [18F]F-AraG PET scans will be performed at 4 different time points following intravenous injection of the PET tracer.
Four whole-body images will be obtained that will reveal biodistribution of [18F]F-AraG at 4 different consecutive time points after intravenous injection.
|
1 day
|
Analyze human dosimetry of [18F]F-AraG
Time Frame: 1 day
|
Time-Activity curves will be graphed by measuring activity in various organs at the 4 time points after tracer injection.
From these time activity curves absorbed radiation will be calculated.
|
1 day
|
Assess acute safety of intravenously injected trace dose of [18F]F-AraG
Time Frame: 8 days
|
Blood and urine samples may be collected at baseline and at 1 and 8 days after injection of [18F]F-AraG to perform metabolic panel, CBC and urine analysis.
Vital signs and EKG will be measured and recorded at baseline, within 3 hours after tracer injection and at 1 and 8 days after tracer injection.
|
8 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Henry VanBrocklin, Ph.D., University of California, San Francisco
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2015
Primary Completion (Actual)
December 31, 2017
Study Completion (Actual)
December 31, 2017
Study Registration Dates
First Submitted
December 16, 2014
First Submitted That Met QC Criteria
December 23, 2014
First Posted (Estimate)
December 24, 2014
Study Record Updates
Last Update Posted (Actual)
May 17, 2018
Last Update Submitted That Met QC Criteria
May 14, 2018
Last Verified
May 1, 2018
More Information
Terms related to this study
Other Study ID Numbers
- 261201300063
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
Clinical Trials on [18F]F-AraG
-
CellSight Technologies, Inc.RecruitingNon Small Cell Lung CancerUnited States
-
CellSight Technologies, Inc.Not yet recruitingAdvanced Non Small Cell Lung Cancer
-
CellSight Technologies, Inc.UCSF Imaging Center at China BasinRecruiting
-
CellSight Technologies, Inc.University of Iowa Hospitals & ClinicsNot yet recruiting
-
CellSight Technologies, Inc.Oregon Health and Science University; Stanford UniversityRecruitingCorrelate Tracer Uptake to TCell Tumor Infiltration & CkIT BenefitUnited States
-
Amsterdam UMC, location VUmcBoehringer IngelheimRecruitingAdvanced Stage Non-small Cell Lung CancerNetherlands
-
Amsterdam UMC, location VUmcRecruitingNon-Small Cell Lung CancerNetherlands
-
Stanford UniversityCellSight Technologies, Inc.RecruitingNon-Hodgkin's LymphomaUnited States
-
University of California, DavisCellSight Technologies, Inc.Enrolling by invitationLung Cancer, Nonsmall CellUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Stand Up To Cancer; CellSight Technologies, Inc.TerminatedNon-small Cell Lung Cancer (NSCLC)United States